# A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

> **NCT07018700** · PHASE3 · RECRUITING · sponsor: **Merz Therapeutics GmbH** · enrollment: 990 (estimated)

## Conditions studied

- Episodic Migraine

## Interventions

- **DRUG:** Xeomin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07018700
- **Lead sponsor:** Merz Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-21
- **Primary completion:** 2027-03
- **Final completion:** 2027-10
- **Target enrollment:** 990 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018700, "A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT07018700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*